iCOGS
Illumina's Q2 Array Sales Rise 3 Percent on Demand for Infinium, BlueGnome Chips, Consumer Genetics
Premium
Illumina's microarray business continued to grow in the second quarter, with customer demand for its Omni and Core families of genotyping arrays, contributions from recent addition BlueGnome, and sales to direct-to-consumer genetics firms such as 23andMe and Ancestry.com pushing
Illumina genotyping arrays are at the heart of an ongoing research effort that seeks to identify the heritability and genetic risk profiles of several cancers and their related subtypes.
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
Nat Genet. 2013 Apr;45(4):385-91.
Eeles R, Olama A, Benlloch S, et al.